EBQ:Sgarbossa Criteria Study - Revision history

Danbot: Added Study Design and Interventions sections

2026-03-21T22:44:17Z

Added Study Design and Interventions sections

@@ Line 34: / Line 34: @@
 ==Criteria==
 {{Sgarbossa Criteria}}
 ==Population==
@@ Line 49: / Line 55: @@
 ===Exclusion Criteria===
 Patients without [[LBBB]]
 ==Outcomes==

Mholtz at 22:42, 4 February 2017

2017-02-04T22:42:03Z

← Older revision		Revision as of 22:42, 4 February 2017
Line 83:		Line 83:
	==Funding==		==Funding==
	Grant from Bayer, Genentech, CIBA–Corning, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.		Grant from Bayer, Genentech, CIBA–Corning, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.

			==See Also==
			*[[Sgarbossa's criteria]]

	==References==		==References==
	<references/>		<references/>

	~~==See Also==~~
	*[[Sgarbossa's criteria]]

	[[Category:EBQ]]		[[Category:EBQ]]
	[[Category:Cardiology]]		[[Category:Cardiology]]

Ostermayer: Text replacement - "Category:Cards" to "Category:Cardiology"

2016-03-22T13:53:20Z

Text replacement - "Category:Cards" to "Category:Cardiology"

← Older revision		Revision as of 13:53, 22 March 2016
Line 91:		Line 91:

	[[Category:EBQ]]		[[Category:EBQ]]
	[[Category:~~Cards~~]]		[[Category:Cardiology]]

Rossdonaldson1: /* Sources */

2015-06-29T12:41:50Z

Sources

← Older revision		Revision as of 12:41, 29 June 2015
Line 84:		Line 84:
	Grant from Bayer, Genentech, CIBA–Corning, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.		Grant from Bayer, Genentech, CIBA–Corning, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.

	==~~Sources~~==		==References==
	<references/>		<references/>

Rossdonaldson1 at 03:57, 28 November 2014

2014-11-28T03:57:53Z

← Older revision		Revision as of 03:57, 28 November 2014
Line 31:		Line 31:

	ECGs of patients with confirmed MIs from the GUSTO-1 trial were blindly compared with ECGs of control patients with LBBB from the Duke Databank for Cardiovascular Disease. The ECG criteria for MI in the presence of LBB was then tested against patients with chest pain and acute LBBB.		ECGs of patients with confirmed MIs from the GUSTO-1 trial were blindly compared with ECGs of control patients with LBBB from the Duke Databank for Cardiovascular Disease. The ECG criteria for MI in the presence of LBB was then tested against patients with chest pain and acute LBBB.

			==Criteria==
			{{Sgarbossa Criteria}}

	==Population==		==Population==

Rossdonaldson1 at 03:42, 28 November 2014

2014-11-28T03:42:19Z

← Older revision		Revision as of 03:42, 28 November 2014
Line 83:		Line 83:
	==Sources==		==Sources==
	<references/>		<references/>

			==See Also==
			*[[Sgarbossa's criteria]]

	[[Category:EBQ]]		[[Category:EBQ]]
	[[Category:Cards]]		[[Category:Cards]]

Ostermayer: /* Major Points */

2014-04-26T09:46:39Z

Major Points

← Older revision		Revision as of 09:46, 26 April 2014
Line 26:		Line 26:
	# ST-segment depression in leads V1, V2 or V3 with a score of 3		# ST-segment depression in leads V1, V2 or V3 with a score of 3
	# ST-segment Elevation of atleast 5 mm with discordance with the QRS complex with a score of 2		# ST-segment Elevation of atleast 5 mm with discordance with the QRS complex with a score of 2

	With a score >3 90% of those with positive criteria will have STEMI ('''Good Speciﬁcity''')		With a score >3 90% of those with positive criteria will have STEMI ('''Good Speciﬁcity''')
	But with negative criteria it doesn't help that much ('''Low sensitivity''')		But with negative criteria it doesn't help that much ('''Low sensitivity''')

	*ECGs of patients with confirmed MIs from the GUSTO-1 trial were blindly compared with ECGs of control patients with LBBB from the Duke Databank for Cardiovascular Disease. The ECG criteria for MI in the presence of LBB was then tested against patients with chest pain and acute LBBB.		ECGs of patients with confirmed MIs from the GUSTO-1 trial were blindly compared with ECGs of control patients with LBBB from the Duke Databank for Cardiovascular Disease. The ECG criteria for MI in the presence of LBB was then tested against patients with chest pain and acute LBBB.

	==Population==		==Population==

Ostermayer: /* Criticisms & Further Discussion */

2014-04-26T09:46:05Z

Criticisms & Further Discussion

← Older revision		Revision as of 09:46, 26 April 2014
Line 74:		Line 74:
	==Criticisms & Further Discussion==		==Criticisms & Further Discussion==
	*The Sgarbossa criteria have not been incorporated into the AHA STEMI guidelines and new LBBB has been removed from the current AHA recommendations for activation of PCI.<ref>Q. Cai, N. Mehta, E.B. Sgarbossa, S.L. Pinski, G.S. Wagner, R.M. Califf, and A. Barbagelata, "The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?", American heart journal, 2013.[http://www.ncbi.nlm.nih.gov/pubmed/24016487 PDF]</ref>		*The Sgarbossa criteria have not been incorporated into the AHA STEMI guidelines and new LBBB has been removed from the current AHA recommendations for activation of PCI.<ref>Q. Cai, N. Mehta, E.B. Sgarbossa, S.L. Pinski, G.S. Wagner, R.M. Califf, and A. Barbagelata, "The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?", American heart journal, 2013.[http://www.ncbi.nlm.nih.gov/pubmed/24016487 PDF]</ref>
	*Although the criteria is highly specific it lacks sensitivity and can result in ~~excess cath~~ lab activation.<ref>D.M. Larson, K.M. Menssen, S.W. Sharkey, S. Duval, R.S. Schwartz, J. Harris, J.T. Meland, B.T. Unger, and T.D. Henry, ""False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction.", JAMA : the journal of the American Medical Association, 2007</ref>
			*Although the criteria is highly specific it lacks sensitivity and can result in false positive catheterization lab activation.<ref>D.M. Larson, K.M. Menssen, S.W. Sharkey, S. Duval, R.S. Schwartz, J. Harris, J.T. Meland, B.T. Unger, and T.D. Henry, ""False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction.", JAMA : the journal of the American Medical Association, 2007</ref>

	==Funding==		==Funding==

Ostermayer at 09:45, 26 April 2014

2014-04-26T09:45:20Z

← Older revision		Revision as of 09:45, 26 April 2014
Line 13:		Line 13:
	\| fulltexturl= http://www.nejm.org/doi/full/10.1056/NEJM199602223340801		\| fulltexturl= http://www.nejm.org/doi/full/10.1056/NEJM199602223340801
	\| pdfurl=http://www.nejm.org/doi/pdf/10.1056/NEJM199602223340801		\| pdfurl=http://www.nejm.org/doi/pdf/10.1056/NEJM199602223340801
	\| status=~~Under Review~~		\| status=Complete
	}}		}}
	==Clinical Question==		==Clinical Question==

Ostermayer: /* Outcomes */

2014-04-26T09:45:04Z

Outcomes

← Older revision		Revision as of 09:45, 26 April 2014
Line 61:		Line 61:
	\|}		\|}

	;Validation Segment for Sgarbosa Score ≥3		;Validation Segment for Sgarbosa Score ≥3 to determine prescience of a STEMI
	''Derivation sample vs Validation Sample''		''Derivation sample vs Validation Sample''
	*Sensitivity: ''78% vs 36%''		*Sensitivity: ''78% vs 36%''